Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Oncotarget|November 1, 2014
A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localizationMin He, Xin Hu, Li Chen, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2015
Tangential migration of neuronal precursors of glutamatergic neurons in the adult mammalian brainGerald J Sun, Yi Zhou, Ryan P Stadel, et al.
Investigative Ophthalmology & Visual Science|September 28, 2019
Expanding the Phenotypic and Genotypic Landscape of Nonsyndromic High Myopia: A Cross-Sectional Study in 731 Chinese PatientsXue-Bi Cai, Yi-Han Zheng, De-Fu Chen, et al.
International Journal of Cancer|March 16, 2017
The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencingGuan-Tian Lang, Jin-Xiu Shi, Xin Hu, et al.
The Journal of Clinical Investigation|April 29, 2025
Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2- breast cancerShao-Ying Yang, Ming-Liang Jin, Lisa Andriani, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 12, 2010
Age-dependent maintenance of motor control and corticostriatal innervation by death receptor 3Jason Peter Twohig, Malcolm I Roberts, Nuria Gavalda, et al.
Breast Cancer Research and Treatment|May 17, 2008
Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relativesA-Yong Cao, Juan Huang, Zhen Hu, et al.
Breast Cancer Research and Treatment|May 1, 2008
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relativesA-Yong Cao, Juan Huang, Zhen Hu, et al.
BMJ (Clinical Research Ed.)|December 23, 2025
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trialYin Liu, Yue Gong, Xiu-Zhi Zhu, et al.
Cell Research|March 27, 2023
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trialYin Liu, Xiu-Zhi Zhu, Yi Xiao, et al.
Pageof 14